Here's why the CSL (ASX:CSL) share price is up 5% in a month

Here's two happenings that might explain CSL's recent gains.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The last 30 days have been good to the CSL Limited (ASX: CSL) share price.

Its gained 4.97% over the month to today, despite releasing no news to the market. In fact, the last time the ASX heard price-sensitive news from CSL was back in early May.

Right now, the CSL share price is $292.73.

Let's take a look at what's been driving it lately.

doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares

Image source: Getty Images

What's up with the CSL share price?

It's been a quiet, yet productive month on the ASX for CSL.

While it has been in and out of the news due to its contract to produce AstraZeneca's COVID-19 vaccine, the company itself hasn't announced anything.

So, it's a mystery as to why the CSL share price is gaining. Or is it? Here are two happenings that might explain why the healthcare giant's stock is surging.

Australian dollar

CSL is an Australian company, but most of its profit comes from overseas.

In financial year 2020, only 1.5% of CSL's external operating revenue came from Australia.

Most of its income came from the United States. And right now, $1 Australian is only getting US$0.73.

That means when CSL earns income in US dollars, it gets more Aussie bucks back in its pocket. Although, the company does report in US dollars, so we likely won't see the impact of the currency fluctuation in its upcoming full year report.

mRNA possibility

It's also less than a month since the federal government's approach to the market, calling for companies to submit their interest in creating mRNA vaccines, closed to new applicants.

According to reporting by ABC News, Industry Minister Christian Porter confirmed CSL has put itself forward to be considered as an mRNA vaccine manufacturer.

The anticipation of finding out who has won the federal government's favour might also be boosting the CSL share price.

Of course, CSL already makes the AstraZeneca vaccine in its Melbourne facility.

CSL share price snapshot

The month that's been has added to CSL's strong performance on the ASX.

The CSL share price is currently 2% higher than it was at the start of 2021. It has also gained 3% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Happy man working on his laptop.
Healthcare Shares

This ASX healthcare stock is up 70% in a year and climbing again today

Another strong quarter keeps the Cogstate stock in focus.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX healthcare stock could more than double according to Canaccord Genuity

It's shaping up as a big year for this drug developer.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Broker Notes

Why beaten down CSL shares now offer 'long-term appeal'

A leading expert gives his outlook for CSL’s beaten down shares.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

Why Neuren shares are rebounding on Wednesday after a brutal 2026 sell-off

Neuren shares jump after DAYBUE STIX expands across the US.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

After a 30% 2026 slide, Pro Medicus shares are rocketing again

Pro Medicus shares jump after another major contract win.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Healthcare Shares

Could the CSL share price reach $200 in 2026?

The biotech's shares have had a tough run, but the long-term story may not be broken.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Pro Medicus announces $23m US contract

Pro Medicus has signed a $23 million, five-year cloud imaging contract with University of Maryland Medical System.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

2 classy ASX healthcare stocks to buy before the next market surge

If sentiment shifts, these global powerhouses could lead the rally.

Read more »